Antibody-drug conjugates (ADCs) illustrate the continued evolution of treatment options across HER2-positive breast cancer, hormone receptor (HR)positive, HER2-negative breast cancer, and triple-negative breast cancer (TNBC). Following the success of fam-trastuzumab deruxtecan-nxki (Enhertu) in the phase 3 DESTINY-Breast03 trial (NCT03529110), other ADCs are likely to enter the treatment fold in the future, according to William J. Gradishar, MD.
What we will likely have in the coming years is a series of ADCs that we can use that will extend the duration of therapy and options for patients, Gradishar said in an interview with OncLive following an Institutional Perspectives in Cancer (IPC) webinar on breast cancer.
In the interview, Gradishar spoke about the expansion of ADCs across subsets of breast cancer, along with emerging treatment options within each space. Gradishar is the Betsy Bramsen professor of Breast Oncology, a professor of medicine (hematology and oncology) at the Feinberg School of Medicine, and chief of Hematology and Oncology in the Department of Medicine at Northwestern Medicine.
Gradishar: In the HER2-positive space, there have been major advances in the past many years. It seems like every year we get new drugs, and thats a great thing for [clinicians] and patients [because] its improving patient outcomes. I focused on the evolving landscape in metastatic HER2-positive breast cancer and the emergence of ADCs. [This includes] not only ado-trastuzumab emtansine [T-DM1; Kadcyla] but also the emergence of trastuzumab deruxtecan, as well as the results from other trials and new drugs that are still in development.
What this is showing us is that we have a series of drugs to try. Even when a patient develops disease progression on one [treatment], theres the probability that not only will we have [another agent] to offer [patients] but we have the high probability that theyll benefit from it.
The DESTINY-Breast03 trial showed that trastuzumab deruxtecan is an excellent drug that can be used after patients progress on a [pertuzumab (Perjeta), trastuzumab (Herceptin), and docetaxel] regimen, so T-DM1 will likely get moved back [in treatment sequencing].
I covered other ADCs that are in development, including the results of the phase 3 TULIP trial [NCT03262935] with vic-trastuzumab duocarmazine, which looked better than alternative options that were used for standard of care.
The other area that I talked about was new TKIs, focusing on the phase 2 HER2CLIMB trial [NCT02614794] with tucatinib [Tukysa]. [I discussed] the results of the overall trial, which showed a superior outcome for patients getting [tucatinib, trastuzumab, and capecitabine (Xeloda)] compared with trastuzumab and capecitabine [with placebo]. [I specifically addressed] the enhanced benefits seen in patients with brain metastases. This is the first trial that focused on that subset of patients, where its shown that including tucatinib had a marked effect on central nervous system [CNS] progression-free survival [PFS] and overall survival [OS] in those patients.
There are anecdotes with other HER2-directed therapies for CNS brain metastases, but [tucatinib] is one of the most compelling stories so far. Trastuzumab deruxtecan is starting to develop some data [in patients with brain metastases], but [data] are clearly the most robust for tucatinib in this setting.
The final thing I talked about was subcutaneous trastuzumab/pertuzumab, which is an option for patients who are getting [intravenous] trastuzumab/pertuzumab. [These 2 treatment administrations] are equally effective [with] no new toxicities. [The subcutaneous administration adds] an element of convenience, both in terms of time in the chair and [length] of infusion. That is a good option for patients.
One [area I discussed] was ADCs, in this case, sacituzumab govitecan-hziy [Trodelvy], which is an ADC that targets TROP2. [Previous] data from the phase 3 ASCENT trial [NCT02574455] demonstrated that sacituzumab govitecan was superior to alternative chemotherapy options. The effect was seen regardless of [low, medium, or high] TROP2 expression. Patients who received sacituzumab govitecan had a better outcome, regardless of whether they harbored a BRCA mutation.
Where we must consider our decision making is in patients who are PD-L1 positive. In patients who are PD-L1 positive, we would consider immunotherapy. There are data showing that pembrolizumab [Keytruda] added to chemotherapy improves overall outcomes for patients with a combined positive score greater than 10. Most [clinicians] would proceed with immunotherapy first for a patient with metastatic TNBC. Until it stops working, [immunotherapy] would continue. However, when it does [stop working], a drug such as sacituzumab govitecan could be considered for lines of therapy beyond immunotherapy.
In patients with early disease, the phase 3 KEYNOTE-522 trial [NCT03036488] demonstrated that neoadjuvant chemotherapy plus pembrolizumab vs chemotherapy alone enhanced not only the pathological complete response rate, but, with long follow-up, event-free survival [EFS]. In the preoperative setting, patients do not need to be PD-L1 positive. Pembrolizumab can be used [regardless of PD-L1 status]. For most patients who fit the criteria for KEYNOTE-522, we would now use a pembrolizumab-based regimen with chemotherapy preoperatively. [Patients with] node-positive tumors bigger than 2 cm are those who we would consider for preoperative therapy.
There are things well have to think about for those patients who have still have residual disease after surgery who get preoperative pembrolizumab. Do you simply give them [adjuvant] pembrolizumab alone, or pembrolizumab with capecitabine? If patients harbor a BRCA mutation, would you add a PARP inhibitor? These are all questions that we dont have clear answers on, but those are expanding options for patients who remain at risk for disease recurrence.
Dr Rao gave us an overview of the role of CDK4/6 inhibitors in the metastatic setting and [shared] emerging data in the adjuvant setting. In the metastatic setting, she covered some of the updates, particularly with ribociclib [Kisqali] and fulvestrant [Faslodex], which clearly demonstrates an OS benefit. All the CDK4/6 inhibitor trials with palbociclib [Ibrance],abemaciclib [Verzenio], or ribociclib, as first- or second-line therapy, all showed an improvement in PFS.
We are starting to see the emergence of an OS benefit, particularly with ribociclib and abemaciclib, and more recently with palbociclib to a smaller degree. There is a consistency in the data. Some might argue that the data with ribociclib are the most compelling, particularly when combined with fulvestrant in the second-line setting, but the general idea is that patients should be getting a CD4/6 inhibitor. Theyre all associated with improvements in outcome, and all have manageable [adverse] effect [AE] profiles.
In the adjuvant setting, weve had data with palbociclib that did not show an advantage to adding it to [treatment for] high-risk patients, either in those with residual disease or as an adjuvant therapy. We still have data that has not reported from the phase 3 NATALEE trial [NCT03701334] with ribociclib.
The one data set that we have positive data from is the phase 3 monarchE trial [NCT03155997] with abemaciclib, which [examined] patients who are at higher risk. They could have had more than 3 positive nodes, or if they had fewer than 4 positive nodes, then they had to have other [high-risk] features, [regarding] tumor size or proliferation, that would have conferred a greater risk of recurrence. What was demonstrated in that trial, with short follow-up, was that there was a clear benefit with abemaciclib. When the trial data were first presented, a minority of patients had gone through the entire duration of abemaciclib therapy of 2 years. Now with longer follow-up, more of the total pool of patients have completed their abemaciclib therapy. The data still favor the use of abemaciclib. Weve started using [abemaciclib with endocrine therapy] in patients who fit the criteria for the monarchE trial. Its been included in the ASCO guidelines and the NCCN guidelines as an option for patients.
Dr Kalinsky, who was the presenter of the phase 3 RxPONDER trial [NCT01272037] when it first was presented, gave an overview of the molecular tools we have to decide prognosis and determine the benefit from chemotherapy. He briefly covered the phase 3 TAILORx trial [NCT00310180], which was conducted in node-negative patients and served as the basis for the RxPONDER trial, which was conducted in higher-risk patients with 1 to 3 positive nodes.
From [RxPONDER], we were able to identify a subset of patients with node-positive disease where we would have almost universally recommended chemotherapy in the past. There is a subset of patients, based not only on their recurrence score but also clinical features and menopausal status, where we can defer chemotherapy and not compromise their overall outcome. Dr Kalinsky discussed the RxPONDER trial and its nuances, particularly as it relates to premenopausal vs postmenopausal women and where we might draw the line on who must get chemotherapy and who would not benefit from it.
That [assay] has been a practice-changing tool that we now employ daily in our practice, just as we did with the TAILORx data for node-negative patients. Dr. Kalinsky put into perspective all the data and nicely reviewed how clinicians would employ this data to make treatment decisions in this setting.
The TAILORx trial is an older data set at this point. Based on that data, we can identify patients at very low risk of recurrence who dont require chemotherapy. [As with] RxPONDER, there are many patients with node-negative disease who would have universally gotten chemotherapy [in the past]. Now, because of long-term data from the TAILORx trial, we can feel comfortable avoiding chemotherapy in a significant fraction of patients who would have likely gotten chemotherapy in the past because it does not compromise their outcomes.
The IPC webinar and discussions by both myself and my colleagues reflect that weve made progress in almost every silo of breast cancer and every strategy we use to reduce risk and to identify patients who can avoid or need specific therapies. [Clinicians] sometimes have to have a longer perspective to understand where we started from, and its one of the benefits of being around for a while. Seeing what we were doing 20 years ago was, by some measure, somewhat crude. We have come a long way in terms of dividing breast cancer into subsets, developing therapies for each subset, using molecular tools to identify patients at risk, and [learning] how we can mitigate their risk.
That is different from the landscape I had when I was training, and I suspect in 20 years, what were doing now will be viewed as crude. Well have something new that makes everything we do today look [antiquated]. Nonetheless, what we heard about in the four talks reflects all the progress that has been made to benefit patients.
Read the original here:
Antibody-Drug Conjugates Are Carving Out Expanded Roles Throughout Breast Cancer - OncLive
- Exercise promotes a molecular profile in muscle: Research - January 21st, 2023
- Molecular Diagnostics Laboratory < Laboratory Medicine - January 4th, 2023
- Molecular cloning - Wikipedia - December 18th, 2022
- Trends in Molecular Medicine | Journal - ScienceDirect - December 10th, 2022
- Researchers from Insilico Medicine, University of Copenhagen, and University of Chicago unravel molecular secrets hidden in premature aging diseases... - December 2nd, 2022
- Nuclear Medicine and Molecular Imaging Week: October 2-8, 2022 - October 29th, 2022
- Biochemistry & Molecular Biology | Medicine - October 29th, 2022
- Cellular and Molecular Medicine | Faculty of Medicine - October 21st, 2022
- Molecular Diagnostics > Fact Sheets > Yale Medicine - October 21st, 2022
- Expert Reviews in Molecular Medicine | Cambridge Core - October 13th, 2022
- UT Southwestern ranked top health care institution globally for published research by Nature Index - UT Southwestern - October 13th, 2022
- Common Antibiotics Are Losing Their Potency. Researchers Pinpoint Mechanism to Restore It. - NYU Langone Health - October 13th, 2022
- expert reaction to study looking at integrating human stem cell-derived brain-like tissue in the brains of newborn rats - Science Media Centre - October 13th, 2022
- HTG Provides Update on Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery - Yahoo Finance - October 13th, 2022
- UVA Discovers Key Driver of High Blood Pressure - UVA Health Newsroom - October 13th, 2022
- Postdoctoral Fellow in Lung Cancer Genomics job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 311727 - Times Higher Education - October 13th, 2022
- Common cold may increase the risk of long Covid - Earth.com - October 13th, 2022
- Caris' Precision Oncology Alliance Welcomes The Cancer Institute at The University of Tennessee Medical Center - PR Newswire - October 13th, 2022
- Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics - Yahoo... - October 13th, 2022
- Molecular Test Could Improve Early Detection of Pancreatic Cancer - Technology Networks - October 13th, 2022
- UTSW researchers identify key player in cellular response to stress - EurekAlert - October 4th, 2022
- New Antibody Demonstrates Therapeutic Benefits Against Alzheimers - SciTechDaily - October 4th, 2022
- Mount Sinai study uncovers mechanisms of reactive oxygen species in stem cell function and inflammation prevention - EurekAlert - October 4th, 2022
- NovoPath Pushes the Limits of Laboratory Information Systems with Integrated Workflows for Genetic and Molecular Testing - PR Newswire - October 4th, 2022
- Postdoctoral Fellow in Bioinformatics job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 311073 - Times Higher Education - October 4th, 2022
- Breast Cancer Awareness | Nick Jacobs | An unlikely partnership: The United States Army Space and Missile Defense Command and the Joyce Murtha Breast... - October 4th, 2022
- Tackling resistance to HIF2 drugs with an RNA-based therapy - UT Southwestern - October 4th, 2022
- OncoNano Medicine Announces Positive Phase 2 Data for Pegsitacianine as an adjunct to Cytoreductive Surgery of Peritoneal Carcinomatosis - Business... - October 4th, 2022
- SIMATS organizes Induction Ceremony - Afternoonnews - Afternoon News - October 4th, 2022
- ExPath Grad Student Madeline Mayday Awarded Grant from the NIDDK Cooperative Centers of Excellence in Hematology - Yale School of Medicine - September 25th, 2022
- Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes - Business Wire - September 25th, 2022
- New Startups Built From UC Davis Innovations Drive Solutions in Food, Health and Agriculture - University of California, Davis - September 25th, 2022
- Scientists Discover New Cancer Treatment - The Morning News - September 25th, 2022
- Rewriting the Textbook for Precision Medicine - Technology Networks - September 25th, 2022
- Biden says 'The pandemic is over,' but health experts disagree - Chief Healthcare Executive - September 25th, 2022
- Discovery Illuminates How Parkinson's Disease Spreads in The Brain - Weill Cornell Medicine Newsroom - September 25th, 2022
- AI Used to Determine Cause of Alzheimer's and Related Disorders - Inside Precision Medicine - September 25th, 2022
- Looking Ahead in the Treatment of Breast Cancer - Targeted Oncology - September 25th, 2022
- Researchers identify potential biomarker to distinguish two aggressive types of brain tumors in children - EurekAlert - September 25th, 2022
- New study reveals breakthrough infections increase immunity to COVID-19 - OHSU News - September 25th, 2022
- Coronavirus Today: Who's dying of COVID-19 now? - Los Angeles Times - September 25th, 2022
- Hoag Named Radiopharmaceutical Therapy Center of Excellence, Publishes Results of Breast and Prostate Cancer Trials - PR Newswire - September 8th, 2022
- Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines - Yahoo Finance - September 8th, 2022
- Scientists urged the Biden administration to launch an Operation Warp Speed to develop inhaled COVID vaccines. China beat the U.S. to the punch -... - September 8th, 2022
- Foundation Medicine to Share 14 Abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress Demonstrating the Power of Genomic... - September 8th, 2022
- Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader Phase... - September 8th, 2022
- Biden administration says the once-a-year shot phase of the COVID-19 pandemic has arrived - The Boston Globe - September 8th, 2022
- ICCBS welcomes students of MPhil and PhD Programs 2022 - The Academia Mag - September 8th, 2022
- Exciting PhD positions at the European Molecular Biology Laboratory (EMBL) job with EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) | 308114 - Times... - September 8th, 2022
- Congratulations to our NRF award winners | UCT News - University of Cape Town News - September 8th, 2022
- Patients with some forms of aggressive esophageal cancers may benefit from treatment targeting how cells self-regulate - EurekAlert - September 8th, 2022
- Molecular Medicine (M.Sc.) - Georg-August-Universitt Gttingen - August 30th, 2022
- Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated... - August 30th, 2022
- Feinstein Institutes Get $3M From Lupus Research Alliance to Study Remission and Future Therapies - Business Wire - August 30th, 2022
- Unlocking the Power of Precision Medicine the Rheumatology Example - Technology Networks - August 30th, 2022
- When to trust your covid test results and when to question them | Mint - Mint - August 30th, 2022
- Molecular Diagnostics Market Report 2022-2030: Increasing Adoption of Point-Of-Care (Poc) Testing and the Development of Novel Assays Presents... - August 30th, 2022
- Advancing Precision Oncology, Ochsner Health First to Fully Integrate with Tempus and Epic's Genomics Module - Newswise - August 30th, 2022
- Tiny, Touch-Based Sensor Could Help Patients Stay on Top of Their Medications - SciTechDaily - August 30th, 2022
- Stellar Scholars Join CLAS Faculty - UConn Today - University of Connecticut - August 30th, 2022
- COVID-19 gave new urgency to the science of restoring smell - Science News Magazine - August 30th, 2022
- Dr. Sun lab wins R01 from National Institutes of Health to study liver proteins - Wayne State University - August 22nd, 2022
- Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference - GlobeNewswire - August 22nd, 2022
- New Study Identifies How A Group Of Genes Are Linked To Behavioral Conditions - Forbes - August 22nd, 2022
- New gene variant that protects against coronary heart disease uncovered - EurekAlert - August 22nd, 2022
- How a Japanese Herbal Medicine Protects the Gut Against Inflammatory Bowel Disease - Neuroscience News - August 22nd, 2022
- Insilico Medicine presents on AI for drug discovery at 9th Annual Aging Research and Drug Discovery Conference - EurekAlert - August 22nd, 2022
- Why polio is back on the radar of Canadian health officials - Brighter World - August 22nd, 2022
- Angela DeMichele, MD, MSCE, Assesses the Value of I-SPY2 for Neoadjuvant Treatment of Early Breast Cancer - Cancer Network - August 22nd, 2022
- Exciting PhD positions at the European Molecular Biology Laboratory (EMBL) job with EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) | 304753 - Times... - August 22nd, 2022
- Sensor could help patients stay on top of their meds - EurekAlert - August 22nd, 2022
- Trivitron Healthcare launches CoE in metabolomics, genomics, newborn screening and molecular diagnostics - Express Healthcare - August 22nd, 2022
- Research Trends of Moxibustion Therapy for Pain Treatment Over the Pas | JPR - Dove Medical Press - August 22nd, 2022
- Edited Transcript of EXAI.OQ earnings conference call or presentation 18-Aug-22 12:30pm GMT - Yahoo Finance - August 22nd, 2022
- Roche launches COVID-19 test that detects and differentiates the emerging variant of interest BA.2.75 - PR Newswire - August 22nd, 2022
- Will Omicron BA.5 Be the Last of the COVID Variants? - The Epoch Times - August 22nd, 2022
- Many Paths to Failure | Harvard Medical School - Harvard Medical School - August 5th, 2022
- Mitochondrial DNA Mutations Linked to Heart Disease Risk - University of California San Diego - August 5th, 2022
- UC Davis Sets a New Record, Surpasses $1 Billion in Research Funding - University of California, Davis - August 5th, 2022
- A first update on mapping the human genetic architecture of COVID-19 - Nature.com - August 5th, 2022